Ironwood Pharmaceuticals INC Form 4 insider transactions

Director Duane Jon R. acquired 24,311 shares of Ironwood Pharmaceuticals Class A Common Stock on June 18, 2024, as part of the company's non-employee director compensation policy.

Director Julie McHugh acquired 24,311 shares of Ironwood Pharmaceuticals stock on June 18, 2024.

Director Catherine Moukheibir reports acquisition of restricted stock and disposal of shares to cover taxes.

Marla L. Kessler, a director at Ironwood Pharmaceuticals, reported acquiring 24,311 shares of Class A Common Stock on June 18, 2024.

Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported acquiring 24,311 shares of Class A Common Stock on June 18, 2024.

Mark G. Currie, a director at Ironwood Pharmaceuticals, reported acquiring 24,311 shares of Class A Common Stock on June 18, 2024.

Alexander Denner and Sarissa Capital Management report changes in beneficial ownership of Ironwood Pharmaceuticals stock, including the acquisition of shares and indirect ownership through Sarissa Capital's managed funds.

Director Julie McHugh of Ironwood Pharmaceuticals sold 22,766 shares of Class A Common Stock on June 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Catherine Moukheibir sold shares of Ironwood Pharmaceuticals (IRWD) on June 6th and 7th, 2024.

Ironwood Pharmaceuticals CEO Thomas McCourt sold 67,618 shares of Class A Common Stock on May 20, 2024, to cover tax withholding obligations related to vesting of restricted stock units.

Andrew Davis, SVP and Chief Business Officer of Ironwood Pharmaceuticals, sold 22,725 shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Michael Shetzline, CMO, SVP, Head-Res&Drug at Ironwood Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting performance-based restricted stock units.

John Minardo, Chief Legal Officer of Ironwood Pharmaceuticals, sold 17,404 shares of Class A Common Stock to cover tax withholding obligations related to vesting of performance-based restricted stock units.

Sravan Kumar Emany, CFO of Ironwood Pharmaceuticals, disposed of shares to cover tax withholding obligations related to vesting restricted stock units.

Alexander Denner, a director and 10% owner of Ironwood Pharmaceuticals, reported changes in beneficial ownership, including the acquisition of shares and indirect ownership through Sarissa Capital Management LP.

John Minardo, Chief Legal Officer of Ironwood Pharmaceuticals, reports the vesting of performance-based restricted stock units (PSUs) resulting in the acquisition of 32,752 shares of Class A Common Stock.

Sravan Kumar Emany, SVP and CFO of Ironwood Pharmaceuticals, reports the acquisition of 37,120 shares of Class A Common Stock through the vesting of performance-based restricted stock units.

Michael Shetzline, CMO, SVP, Head-Res&Drug at Ironwood Pharmaceuticals, acquired 34,936 shares of Class A Common Stock on March 8, 2024, through the vesting of performance-based restricted stock units.

Andrew Davis, SVP and Chief Business Officer of Ironwood Pharmaceuticals, acquired 37,120 shares of Class A Common Stock on March 8, 2024, following the vesting of performance-based restricted stock units.

CEO Thomas McCourt reports earning shares from performance-based restricted stock units.

Director Duane Jon R. Duane recently purchased 6,920 shares of Ironwood Pharmaceuticals (IRWD) at $8.7 per share, increasing his total holdings to 121,028 shares.

CEO Thomas McCourt of Ironwood Pharmaceuticals reports the acquisition of performance-based restricted stock units.

Sravan Kumar Emany, CFO of Ironwood Pharmaceuticals, recently purchased 10,684 shares of Class A Common Stock at an average price of $9.38, increasing his direct holdings in the company.